GSK3B and bone sarcoma: Stimulation of Wnt/β-catenin signaling with Wnt3a or GSK-3β inhibitor enhanced the proliferation and survival of bone sarcoma cells, whereas antagonism of this pathway with dnTCF4 or siLEF1 had the exact opposite effect.